INS and metabolic syndrome: The plasma levels of apoL1 have been reported to be increased in patients with metabolic syndrome, and an in vitro study has demonstrated that the insulin signaling pathway regulates both the synthesis and the secretion of apoL1 in hepatocytes [38].